Literature DB >> 18483761

Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population.

Khadijeh Onsory1, R C Sobti, Adnan Issa Al-Badran, Masatoshi Watanabe, Taizo Shiraishi, Awtar Krishan, Harsh Mohan, Pushpinder Kaur.   

Abstract

The purpose of this study was to analyse the frequency and type of mutations in the coding region of androgen receptor (AR) and to determine the role of polymorphisms in the intron 1 of ERalpha, exon 5 of ERbeta, intron 7 of progesterone, exon 7 of the aromatase (CYP19) and exon 9 of VDR genes in the risk of prostate cancer. PCR-RFLP analysis of all above the genes was on 100 prostate cancer patients and an equal number of matching controls. The study also included PCR-SSCP analyses of exons 2-8 of AR gene. The genotype containing -/- allele of ERalpha gene was statistically significant for the risk of prostate cancer pose (OR, 2.70; 95% CI, 1.08-6.70, P = 0.032) Rr genotype of ERbeta gene also have a higher risk (OR, 1.65; 95% CI, 0.52-5.23) for prostate cancer. The Cys allele of CYP19 gene was also associated with statistically significant increased risk of prostate cancer (OR; 2.28, 95% CI, 1.20-4.35, P = 0.012). tt genotype of codon 352 of VDR gene showed an OR of 0.43 for (95% CI, 0.13-1.39) and an OR for Tt genotype was 0.65 (95% CI, 0.36-1.16). Taken together, the results showed that in North Indian population, ERalpha and CYP19 genes may be playing a role in the risk of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483761     DOI: 10.1007/s11010-008-9761-1

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  54 in total

1.  Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk.

Authors:  F Modugno; J L Weissfeld; D L Trump; J M Zmuda; P Shea; J A Cauley; R E Ferrell
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

2.  Cloning of human androgen receptor complementary DNA and localization to the X chromosome.

Authors:  D B Lubahn; D R Joseph; P M Sullivan; H F Willard; F S French; E M Wilson
Journal:  Science       Date:  1988-04-15       Impact factor: 47.728

3.  Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men.

Authors:  Javier Hernández; Ivana Balic; Teresa L Johnson-Pais; Betsy A Higgins; Kathleen C Torkko; Ian M Thompson; Robin J Leach
Journal:  J Urol       Date:  2006-02       Impact factor: 7.450

4.  No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer.

Authors:  T P Manolitsas; P Englefield; D M Eccles; I G Campbell
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population.

Authors:  Takahide Fukatsu; Yoshifumi Hirokawa; Tomio Araki; Takuichi Hioki; Tetsuya Murata; Hiroyoshi Suzuki; Tomohiko Ichikawa; Hiromasa Tsukino; Delai Qiu; Takahiko Katoh; Yoshiki Sugimura; Ryuichi Yatani; Taizo Shiraishi; Masatoshi Watanabe
Journal:  Anticancer Res       Date:  2004 Jul-Aug       Impact factor: 2.480

Review 6.  Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3.

Authors:  S Christakos; M Raval-Pandya; R P Wernyj; W Yang
Journal:  Biochem J       Date:  1996-06-01       Impact factor: 3.857

7.  [Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer].

Authors:  Jian-he Liu; Hong-wei Li; Ming Tong; Ming Li; Yan-qun Na
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2004-03-02

8.  Association of prostate cancer with vitamin D receptor gene polymorphism.

Authors:  J A Taylor; A Hirvonen; M Watson; G Pittman; J L Mohler; D A Bell
Journal:  Cancer Res       Date:  1996-09-15       Impact factor: 12.701

9.  Intratissular androgens in benign prostatic hyperplasia and prostatic cancer.

Authors:  K D Voigt; W Bartsch
Journal:  J Steroid Biochem       Date:  1986-11       Impact factor: 4.292

10.  Genomic organization of the human oestrogen receptor gene.

Authors:  M Ponglikitmongkol; S Green; P Chambon
Journal:  EMBO J       Date:  1988-11       Impact factor: 11.598

View more
  15 in total

1.  Haplotype structures and functional polymorphic variants of the drug target enzyme aromatase (CYP19A1) in South Indian population.

Authors:  Gurusamy Umamaheswaran; Steven Aibor Dkhar; Sekar Kalaivani; Raj Anjana; Mohan Revathy; Mohammad Jaharamma; Kulumani Mahadevan Lakshmi Shree; Dharanipragada Kadambari; Chandrasekaran Adithan
Journal:  Med Oncol       Date:  2013-07-28       Impact factor: 3.064

2.  Association between estrogen receptor alpha PvuII polymorphism and prostate cancer risk.

Authors:  Liang Li; Xuening Zhang; Qinglai Xia; Hui Ma; Li Chen; Wenjing Hou
Journal:  Tumour Biol       Date:  2014-01-12

3.  Estrogen receptor alpha gene polymorphisms and risk of prostate cancer: a meta-analysis involving 18 studies.

Authors:  Zhenwei Gu; Gang Wang; Weiguo Chen
Journal:  Tumour Biol       Date:  2014-03-01

4.  Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Authors:  Jie Li; Emma Mercer; Xin Gou; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

5.  CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium.

Authors:  Ruth C Travis; Fredrick Schumacher; Joel N Hirschhorn; Peter Kraft; Naomi E Allen; Demetrius Albanes; Goran Berglund; Sonja I Berndt; Heiner Boeing; H Bas Bueno-de-Mesquita; Eugenia E Calle; Stephen Chanock; Alison M Dunning; Richard Hayes; Heather Spencer Feigelson; J Michael Gaziano; Edward Giovannucci; Christopher A Haiman; Brian E Henderson; Rudolf Kaaks; Laurence N Kolonel; Jing Ma; Laudina Rodriguez; Elio Riboli; Meir Stampfer; Daniel O Stram; Michael J Thun; Anne Tjønneland; Dimitrios Trichopoulos; Paolo Vineis; Jarmo Virtamo; Loïc Le Marchand; David J Hunter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-29       Impact factor: 4.254

Review 6.  Molecular basis for prostate cancer racial disparities.

Authors:  Santosh K Singh; James W Lillard; Rajesh Singh
Journal:  Front Biosci (Landmark Ed)       Date:  2017-01-01

7.  The CYP19A1 (TTTA)n Repeat Polymorphism May Affect the Prostate Cancer Risk: Evidence from a Meta-Analysis.

Authors:  Lei Guo; Yanan Liu; Lijun Liu; Shixiu Shao; Yanwei Cao; Jiaming Guo; Haitao Niu
Journal:  Am J Mens Health       Date:  2021 May-Jun

Review 8.  ESR1 Gene Polymorphisms and Prostate Cancer Risk: A HuGE Review and Meta-Analysis.

Authors:  Yu-Mei Wang; Zu-Wang Liu; Jing-Bo Guo; Xiao-Fang Wang; Xin-Xin Zhao; Xuan Zheng
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

9.  Comprehensive assessment of the association between estrogen receptor of alpha polymorphisms and the risk of prostate cancer: evidence from a meta-analysis.

Authors:  Guang Li; Meng Yang; Xian Li; Shixiong Deng
Journal:  Oncotarget       Date:  2017-09-21

10.  Polymorphisms of vitamin D receptor gene TaqI susceptibility of prostate cancer: a meta-analysis.

Authors:  Xiawei Fei; Nannan Liu; Huifeng Li; Yanting Shen; Jianming Guo; Zhenqi Wu
Journal:  Onco Targets Ther       Date:  2016-03-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.